



## Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures and is intended to be regulated as a medical device.

## Management Team

**Dr. Terrence W. Norchi**  
President, Chief Executive Officer and Director

**Richard E. Davis**  
Chief Financial Officer

## Recent News

Tuesday, September 03, 2019 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference](#)

Monday, August 05, 2019 - 07:50 AM

[Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat](#)

Thursday, May 30, 2019 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the 9th Annual LD Micro Invitational](#)

Monday, May 13, 2019 - 07:45 AM

[Arch Therapeutics, Inc. \\$2.8 Million Registered Direct Offering](#)

Wednesday, April 24, 2019 - 07:50 AM

[Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference \(SAWC\) and Release of a New AC5™ Topical Gel Video](#)

## DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

## Contact Information

**Arch Therapeutics, Inc.**  
235 Walnut Street  
Suite 6  
Framingham, MA 01702

## OTCQB: ARTH



Share Price	\$0.26
Volume	218.98k
Shares Outstanding	173,577,233
Market Cap	\$45.13m
52 Week High	\$0.62
52 Week Low	\$0.25

as of 09/19/2019